المؤلفون: Croft DE; Retina Consultants of Houston, Houston, Texas., Wykoff CC; Retina Consultants of Houston, Houston, Texas; Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas. Electronic address: ccwmd@houstonretina.com., Michels S; Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland., Chakravarthy U; Center for Experimental Medicine, The Queen's University of Belfast, Belfast, United Kingdom., Cruess AF; Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Canada.

المصدر: American journal of ophthalmology [Am J Ophthalmol] 2016 Sep; Vol. 169, pp. xiv-xvi. Date of Electronic Publication: 2016 Jul 30.

نوع المنشور: Editorial

بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1891 (Electronic) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*administration & dosage , Diabetic Retinopathy/*drug therapy , Drug and Narcotic Control/*legislation & jurisprudence , Legislation, Drug/*organization & administration , Macular Degeneration/*drug therapy , Pharmaceutical Preparations/*administration & dosage , Retinal Vein Occlusion/*drug therapy, Clinical Trials, Phase III as Topic ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; European Union ; Humans ; Legislation, Drug/standards ; United States ; Vascular Endothelial Growth Factor A/antagonists & inhibitors

المؤلفون: Freund KB; Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland., Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo C, Tadayoni R, Talks J, Wolf S

المصدر: Retina (Philadelphia, Pa.) [Retina] 2015 Aug; Vol. 35 (8), pp. 1489-506.

نوع المنشور: Consensus Development Conference; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8309919 Publication Model: Print Cited Medium: Internet ISSN: 1539-2864 (Electronic) Linking ISSN: 0275004X NLM ISO Abbreviation: Retina Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Diabetic Retinopathy/*drug therapy , Macular Degeneration/*drug therapy , Macular Edema/*drug therapy , Retinal Vein Occlusion/*drug therapy , Vascular Endothelial Growth Factor A/*antagonists & inhibitors, Algorithms ; Bevacizumab/therapeutic use ; Humans ; Ranibizumab/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Recombinant Fusion Proteins/therapeutic use

المؤلفون: Freund, K. Bailey, Korobelnik, Jean François, Devenyi, Robert, Framme, Carsten, Galic, John, Herbert, Edward, Hoerauf, Hans, Lanzetta, Paolo, Michels, Stephan, Mitchell, Paul, Monés, Jordi, Regillo, Carl, Tadayoni, Ramin, Talks, James, Wolf, Sebastian

مصطلحات موضوعية: Vascular Endothelial Growth Factor A, algorithm, Diabetic Retinopathy, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, aflibercept, Angiogenesis Inhibitors, bevacizumab, Macular Edema, anti-VEGF agents, Macular Degeneration, Ophthalmology, age-related macular degeneration, diabetic macular edema, ranibizumab, retinal vein occlusion, treat-and-extend, Algorithms, Bevacizumab, Humans, Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Retinal Vein Occlusion, Receptors

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3659::6f34540da5093708b4e9126ad213a460
http://hdl.handle.net/11390/1101752